Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

oints) with sham treatment. Improved motor control in the NLX-P101 group was seen at one month and continued virtually unchanged throughout the blinded six month study period.  The improvement in UPDRS motor scores from baseline in the NLX-P101 group was significantly greater than sham subjects over the six month study period (p=0.04). Last month, the one year follow-up results of these primary outcomes were presented at the International Neuromodulation Society's 10th World Congress meeting by Neurologix scientific co-founder Michael G. Kaplitt, M.D., Ph.D., Associate Professor of Neurological Surgery at Weill Cornell Medical College. He reported sustained improvement of an average of 8.2 points in the off-medication UPDRS motor score at one year. Furthermore, while 50% of patients at six months achieved previously defined moderate-to-large clinically meaningful symptom improvements (> 9 points in off-medication UPDRS motor score), 63% of patients achieved such results at one year, with an average 14 point, or 37% improvement in off-medication UPDRS motor scores in this group.

The Company's Phase 2 study findings build upon earlier positive results from the NLX-P101 Phase 1 trial, which appeared in 2007 as a cover article in The Lancet and in a second article in the Proceedings of the National Academy of Sciences. Neurologix plans to submit a Phase 3 protocol to the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment later in 2011.

"Neurologix is committed to providing patients a novel, sustained, long-term option for managing and controlling the debilitating conditions of Parkinson's disease," said Clark A. Johnson, President and Chief Executive Officer of Neurologix. "The statistically significant extension of "ON" time, lessening of medication side effects and favorable safety profile in the treated patient group at 12 months are encouraging results that further support NLX-P101 as a viable treatment op
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/25/2014)... HILL, N.C. , July 25, 2014  Corporate ... challenges, including understanding new advancements in technology and how ... of this, libraries in the pharmaceutical and medical device ... value of the information and services they provide. ... Best Practices, LLC there are many forces of change ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6Forces of Change Reshaping Corporate Libraries & Information Services 2
... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
(Date:7/28/2014)... researchers in Taiwan has developed a new optical technology ... of diabetes sooner, when it is more easily treated. ... trials, it may pave the way for the early ... diabetic autonomic neuropathy, which is common among people with ... progressively affects the autonomic nerves controlling vital organs like ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Top Northridge ... coupon for new patients. Finding a new dentist can be ... dental issues that have gone untreated and worry about how ... Ariz specializes in patients with special concerns and dental needs ... comfortable and right at home. This special coupon can help ...
(Date:7/28/2014)... July 28, 2014 "I injured my shoulder ... said an inventor from Sunnyvale, Calif. "When I slept in ... the market are cumbersome and require too many straps. That ... developed the Multiple Functioning Vest to improve the design of ... so that they heal properly. This helps to speed up ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July ... health insurance this year will face fines of up to ... the Internal Revenue Service says. The Obama administration on ... that some Americans will owe for failing to have health ... monthly national average premium for a bronze-level health plan. ...
(Date:7/28/2014)... 2014 Glidewell Laboratories announced today that ... successfully passed the five-year mark in clinical usage, and ... units prescribed by US dentists. , Even as BruxZir ... good results from respected clinical studies, many dentists expressed ... over extended years of clinical service before they would ...
Breaking Medicine News(10 mins):Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:IRS Caps Fines on Uninsured Americans at $12K for Family of 5 2Health News:BruxZir® Solid Zirconia Surpasses Five Years of Clinical Use 2
... , HARRISBURG, Pa. , Jan. 13 ... launch of an innovative initiative to create clinically proven, ... of care for patients.  The P4 Pathways Program will ... for the treatment of patients with cancer, as well ...
... , NEW YORK , Jan. 13 ... been named president and CEO of Siemens Corporation. Spiegel, an ... on January 18 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ... Senior Partner at Booz & Co. and brings more than ...
... Bradley C. Brennecke , a resident of Pleasant Plain, Ohio ... , pleaded guilty late Tuesday to conspiracy and tax evasion charges before District ... Department and Internal Revenue Service (IRS) announced. , Mrusek and Brennecke, who ... icted in July 2009 and charged with tax ...
... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
... say researchers working with mice , WEDNESDAY, Jan. 13 ... greater understanding of how a brain becomes susceptible to ... some people are resistant to antidepressants. , Scientists think ... -- cause the mental disorders. Antidepressants (such as Prozac) ...
... aged 6-19 still climbing, government study finds , WEDNESDAY, Jan. ... on weight: Obesity in the United States may finally be ... the rates of obesity remain high, with about one-third of ... obesity among already heavy 6- to 19-year-old boys appear to ...
Cached Medicine News:Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 2Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 3Health News:Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative 4Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Two Cincinnati Dentists Plead Guilty to Conspiracy, Tax Evasion on Eve of Trial 2Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: